Company / Cash & Equivalents
FILANA THERAPEUTICS, INC. Cash & Equivalents History
FY2011-FY2015 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$48.6M
FY2015
5-year range
$4.8M / $73.1M
FY2011-FY2015
Trend
-1.6%
vs FY2014
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $73M to $49M over the past 2 years.
Based on SEC 10-K filings.
$49M in FY2015 with a 3-year CAGR of +116.3%.
Declined from $73M to $49M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +116.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +116.3%, indicating consistent growth.
- In FY2015, cash & equivalents decreased 1.6% year-over-year.
- Peak cash & equivalents was recorded in FY2013.
- Lowest cash & equivalents in the period was in FY2012.
Company context
Key Data Points
- Altman Z-Score 3.76 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2015 | $48.6M | -1.6% |
| FY2014 | $49.4M | -32.5% |
| FY2013 | $73.1M | +1424.5% |
| FY2012 | $4.8M | -86.6% |
| FY2011 | $35.8M | - |
As of FY2015 · SEC 10-K · Updated Jun 24, 2026